This $106,160 federal Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) aims to investigate the role of DNA methylation in Mycobacterium tuberculosis (MTB) persistence and antibiotic tolerance. The project, led by Stellenbosch University in South Africa, will demonstrate how DNA methylation impacts the MTB stress response, phenotypic drug resistance, and the formation of persister...
This Project Grant award of $2,248,740.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research by Michigan State University to develop new nitro-containing compounds to treat mycobacterial infections, including tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The key products and services to be delivered include: Optimizing a series of novel nitrofuran compounds, such as the parent...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...
This Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) will provide $108,916 to Kamuzu University of Health Sciences in Malawi to characterize the pharmacokinetic and safety profiles of the antimalarial drugs artemether-lumefantrine plus amodiaquine (ALAQ) in two key target populations: children with severe acute malnutrition and adults living with HIV on dolutegravir-based antiretroviral...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This $1,413,007 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development and evaluation of the CRISPR-TB diagnostic tool for detecting tuberculosis (TB) in children under 5 years old. The University of Washington is the primary grantee and will lead a large prospective study of 400 children with suspected TB. The project aims to expand upon prior successful...
This Project Grant award from the John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $108,237 to Mbarara University of Science and Technology in Uganda to develop and assess the feasibility of a diagnostic tool for post-tuberculosis (TB) lung disease that can be deployed in primary healthcare settings. The key objectives are to: (1) create and validate a clinical diagnostic algorithm for post-TB lung disease, (2) conduct qualitative...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $193,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on August 20, 2024. The award will fund a 5-year research project titled "The Relationship Between HIV Exposure, Contact Networks, and TB in Children Under 5 Years Old." As part of this project, BMC will collaborate with Stellenbosch University in South Africa, which...
This federal Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $113,400 over 5 years to support the development of an HIV cure research program focused on adolescents living with HIV-1 in Botswana. The key objectives are to: 1) identify adolescents with low HIV reservoirs and potential for post-treatment control, 2) evaluate changes in the HIV reservoir over time and enroll eligible participants in an analytical...
This federal Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $559,341 to support research on tuberculosis (TB) in children under 5 years old in Malawi. The award period is from September 20, 2024 to August 31, 2029. The research focuses on two key objectives: 1) evaluating the accuracy of new non-invasive TB diagnostic strategies using stool and urine samples in hospitalized Malawian children under 5, and 2) characterizing the pharmacokinetics of first-line anti-TB medications in this age group with co-prevalent severe acute malnutrition. The work will be conducted through a partnership between Henry Ford Health and Michigan State University Health Sciences, which have extensive expertise in global health research and building local research capacity in low-income countries.